Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — Q3 2022 Earnings Presentation
9 slides from Vivoryon Therapeutics's earnings presentation, Nov 22, 2022
Slide 1: Third Quarter 2022 Results Webcast and Conference Call
THIRD QUARTER 2022 RESULTS WEBCAST AND CONFERENCE CALL November 22, 2022 |Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Vivoryon's Approach to Overcoming the Challenges of AD Drug Development
VIVORYON’S APPROACH TO OVERCOMING THE CHALLENGES OF AD DRUG DEVELOPMENT Oral small molecule inhibitor varoglutamstat targeting multiple hallmarks of AD QPCT/L AS KEY TARGET IN AD VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS High unmet medical need in AD despite recent advances CCL2 Abeta First poten
Slide 4: Varoglutamstat Development Strategy Updates
VAROGLUTAMSTAT DEVELOPMENT STRATEGY UPDATES Key learnings from Alzheimer’s disease clinical landscape: ◆ Patient recruitment and retention in studies ◆ Support participation and reduce discontinuation rates ◆ Endpoint selection ◆ Leverage learnings about therapeutic success in the AD field to suppor
Slide 5: Varoglutamstat Clinical Programs
VAROGLUTAMSTAT CLINICAL PROGRAMS Phase 2b study in 250 patients with Phase 2a/b study in 414 patients with early AD MCI/mild AD Endpoints: safety, ABC scores/ cognition & EEG, Endpoints: safety, attention/working CDR-SB, biomarkers memory, NTB, biomarkers ◆ Run by ADCS, supported by NIH grant ◆ Stud
Slide 6: Optimized & Improved Clinical Development Strategy
OPTIMIZED & IMPROVED CLINICAL DEVELOPMENT STRATEGY Clear Path To Potential Regulatory Approval Extensive Phase 1 and Phase 2 trials Pivotal study or Phase 2b VIVIAD accelerated approval Assessment of safety, tolerability and FDA Fast Track designation efficacy in 250 patients with MCI or mild AD gra
Slide 7: Key Financial Figures
KEY FINANCIAL FIGURES In € million Sep 30, 2022 Sep 30, 2021 Revenue — 10.8 Research and development expenses (16.1) (13.6) General and administrative expenses (4.2) (3.2) Net loss for the period (18.9) (7.3) In € million Sep 30, 2022 Dec 31, 2021 Cash and cash equivalents 19.8 14.7 Total equity 20.
Slide 8: Q&A
Q&A
Slide 9: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany Munich Franz-Josef-Delonge-Str. 5 81249 München Germany info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Q3 2022 Earnings Presentation on 6ix